{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:04:23Z","timestamp":1792461863196,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Various human skeletal disorders are thought to be caused by mutations in fibroblast growth factor receptor 3 (FGFR3). These result in chronic FGFR3 hyperactivation and inhibition of bone growth. One such disorder, thanatophoric dysplasia, the most common form of sporadic, lethal dwarfism, is associated frequently with cysteine substitutions (G370C, S371C, and Y373C) in the extracellular juxtamembrane region of the receptor. These mutations have been suggested to induce disulfide-mediated receptor dimerization and constitutive activation. An adjacent cysteine substitution (G375C) leads to a less severe form of human dwarfism, achondroplasia, suggesting that the intensity of FGFR3 activation by these cross-links may be position dependent. To test this hypothesis, we have sequentially replaced each amino acid at positions 370-375 of FGFR3 with cysteine. Expression of each of these mutant forms in 293T cells led to their spontaneous, ligand-independent dimerization and increased basal phosphorylation. Wild-type (WT) FGFR3 became dimerized and phosphorylated only on FGF stimulation. Among the mutants, only two (G370C and S371C) caused high basal phosphorylation with significantly increased constitutive levels of mitogen-activated protein kinase (MAPK) phosphorylation and c-fos transcription. This activity was probably caused by mutant homodimer pairs, because WT-mutant heterodimers were observed only in the presence, but not in the absence, of FGF1. The high spontaneous activity of the mutants in positions 370-371, unlike those in 372-375, affirms their known involvement with thanatophoric dysplasia. We conclude that the G370C and S371C mutant receptors spontaneously dimerize in the correct spatial orientation required for effective signal transduction, whereas the 372-5 mutants, like the WT receptor, may achieve this orientation only on ligand binding.<\/jats:p>","DOI":"10.1359\/jbmr.2002.17.5.860","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T21:12:20Z","timestamp":1146085940000},"page":"860-868","source":"Crossref","is-referenced-by-count":70,"title":["Differential Activation of Cysteine-Substitution Mutants of Fibroblast Growth Factor Receptor 3 Is Determined by Cysteine Localization"],"prefix":"10.1093","volume":"17","author":[{"given":"Rivka","family":"Adar","sequence":"first","affiliation":[{"name":"Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel"},{"name":"ProChon Biotech, Ltd., Kiryat Weizmann, Science Park, Rehovot, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Monsonego-Ornan","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel"},{"name":"ProChon Biotech, Ltd., Kiryat Weizmann, Science Park, Rehovot, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pe'er","family":"David","sequence":"additional","affiliation":[{"name":"ProChon Biotech, Ltd., Kiryat Weizmann, Science Park, Rehovot, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Yayon","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel"},{"name":"ProChon Biotech, Ltd., Kiryat Weizmann, Science Park, Rehovot, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019090664500_bib1","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1096\/fasebj.6.15.1464370","article-title":"Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity","volume":"6","author":"Givol","year":"1992","journal-title":"FASEB J"},{"key":"2024013019090664500_bib2","first-page":"1","article-title":"Structural and functional diversity in the FGF receptor multigene family","volume":"160","author":"Johnson","year":"1993","journal-title":"Adv Cancer Res"},{"key":"2024013019090664500_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-230X(08)60305-X","article-title":"The FGF family of growth factors and oncogenes","volume":"159","author":"Basilico","year":"1992","journal-title":"Adv Cancer Res"},{"key":"2024013019090664500_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0955-2235(89)90012-4","article-title":"The fibroblast growth factor family: Structural and biological properties","volume":"1","author":"Klagsbrun","year":"1989","journal-title":"Prog Growth Factor Res"},{"key":"2024013019090664500_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Folkman","year":"1987","journal-title":"Science"},{"key":"2024013019090664500_bib6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0960-9822(95)00102-3","article-title":"Function of fibroblast growth factors and their receptors","volume":"5","author":"Wilkie","year":"1995","journal-title":"Curr Biol"},{"key":"2024013019090664500_bib7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJM197010012831404","article-title":"Endochondral ossification in achondroplastic dwarfism","volume":"283","author":"Rimoin","year":"1970","journal-title":"N Engl J Med"},{"key":"2024013019090664500_bib8","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1093\/hmg\/4.11.2175","article-title":"Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I","volume":"4","author":"Tavormina","year":"1995","journal-title":"Hum Mol Genet"},{"key":"2024013019090664500_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/hmg\/5.4.509","article-title":"Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1)","volume":"5","author":"Rousseau","year":"1996","journal-title":"Hum Mol Genet"},{"key":"2024013019090664500_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ng0595-11","article-title":"Stop codon FGFR3 mutations in thanatophoric dwarfism type 1","volume":"10","author":"Rousseau","year":"1995","journal-title":"Nat Genet"},{"key":"2024013019090664500_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/371252a0","article-title":"Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia","volume":"371","author":"Rousseau","year":"1994","journal-title":"Nature"},{"key":"2024013019090664500_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","article-title":"Mutations in transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, Achondroplasia","volume":"78","author":"Shiang","year":"1994","journal-title":"Cell"},{"key":"2024013019090664500_bib13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1749-6632.1996.tb56257.x","article-title":"Hypochondroplasia: Molecular analysis of the fibroblast growth factor receptor 3 gene","volume":"785","author":"Bellus","year":"1996","journal-title":"Ann NY Acad Sci"},{"key":"2024013019090664500_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng0395-321","article-title":"Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3","volume":"9","author":"Tavormina","year":"1995","journal-title":"Nat Genet"},{"key":"2024013019090664500_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/MCB.20.2.516-522.2000","article-title":"The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation","volume":"20","author":"Monsonego-Ornan","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2024013019090664500_bib16","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1128\/MCB.18.9.5371","article-title":"Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface","volume":"18","author":"Burke","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2024013019090664500_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/2965","article-title":"An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation","volume":"5","author":"Livnah","year":"1998","journal-title":"Nat Struct Biol"},{"key":"2024013019090664500_bib18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1126\/science.283.5404.987","article-title":"Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation","volume":"283","author":"Livnah","year":"1999","journal-title":"Science"},{"key":"2024013019090664500_bib19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0022-1759(00)00247-7","article-title":"Sorting polyclonal antibodies into functionally distinct fractions using peptide phage display: \u2018A library on top of a library.\u2019","volume":"242","author":"Moshitch-Moshkovitz","year":"2000","journal-title":"J Immunol Methods"},{"key":"2024013019090664500_bib20","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1093\/nar\/16.15.7351","article-title":"A general method of in vitro preparation and specific mutagenesis of DNA fragments: Study of protein and DNA interactions","volume":"16","author":"Higuchi","year":"1988","journal-title":"Nucleic Acid Res"},{"key":"2024013019090664500_bib21","first-page":"71","article-title":"Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I","volume":"9","author":"d'Avis","year":"1998","journal-title":"Cell Growth Differ"},{"key":"2024013019090664500_bib22","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1074\/jbc.M005088200","article-title":"Antiproliferative effects of insulin-like growth factor-binding protein-3 in mesenchymal chondrogenic cell line RCJ3.1C5.18. relationship to differentiation stage","volume":"276","author":"Spagnoli","year":"2001","journal-title":"J Biol Chem"},{"key":"2024013019090664500_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1042\/bj3420677","article-title":"Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differentiation and terminal differentiation of chondrocytic cells in vitro","volume":"342","author":"Weksler","year":"1999","journal-title":"Biochem J"},{"key":"2024013019090664500_bib24","doi-asserted-by":"crossref","first-page":"15933","DOI":"10.1074\/jbc.M909299199","article-title":"&gt;A novel type I fibroblast growth factor receptor activates mitogenic signaling in the absence of detectable tyrosine phosphorylation of FRS2","volume":"275","author":"Lopez","year":"2000","journal-title":"J Biol Chem"},{"key":"2024013019090664500_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/j.1460-2075.1996.tb00384.x","article-title":"Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia","volume":"15","author":"Webster","year":"1996","journal-title":"EMBO J"},{"key":"2024013019090664500_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0168-9525(97)01131-1","article-title":"FGFR activation in skeletal disorders: Too much of a good thing","volume":"13","author":"Webster","year":"1997","journal-title":"Trends Genet"},{"key":"2024013019090664500_bib27","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1128\/MCB.17.7.4169","article-title":"Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells","volume":"17","author":"Thompson","year":"1997","journal-title":"Mol Cell Biol"},{"key":"2024013019090664500_bib28","doi-asserted-by":"crossref","first-page":"35250","DOI":"10.1074\/jbc.273.52.35250","article-title":"Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation","volume":"273","author":"Raffioni","year":"1998","journal-title":"J Biol Chem"},{"key":"2024013019090664500_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1091\/mbc.12.4.931","article-title":"Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, stat activation, and phosphatidylinositol 3-kinase activation","volume":"12","author":"Hart","year":"2001","journal-title":"Mol Biol Cell"},{"key":"2024013019090664500_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.onc.1201936","article-title":"Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding","volume":"17","author":"Landgren","year":"1998","journal-title":"Oncogene"},{"key":"2024013019090664500_bib31","doi-asserted-by":"crossref","first-page":"D165","DOI":"10.2741\/Klint","article-title":"Signal transduction by fibroblast growth factor receptors","volume":"4","author":"Klint","year":"1999","journal-title":"Front Biosci"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2002.17.5.860","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/17\/5\/860\/56470429\/5650170514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/17\/5\/860\/56470429\/5650170514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:05:02Z","timestamp":1710342302000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/17\/5\/860-868\/7592429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2002,5,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2002.17.5.860","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,5,1]]},"published":{"date-parts":[[2002,5,1]]}}}